MedTrace Logo

Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis

NCT07503587 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2026-03-31

No results posted yet for this study

Summary

This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Conditions

  • Progressive Pulmonary Fibrosis

Interventions

DRUG

HSK44459

HSK44459 taken orally twice daily in the morning and in the evening for 52weeks.

DRUG

Placebo

Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 52 weeks

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-05
Primary Completion
2028-12-30
Completion
2029-03-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07503587 on ClinicalTrials.gov